Call Button
If you need to lie down or are lacking concentration due to headaches or migraines, Book your appointment today

Migraines are not merely headaches; they are debilitating episodes of intense pain, often accompanied by nausea, sensitivity to light and sound, and in severe cases, temporary paralysis, or visual disturbances. For those who suffer from migraines on the Gold Coast, these attacks are not just occasional inconveniences but persistent, life-altering challenges. According to recent statistics, migraine affects over 15% of the Gold Coast population (1), with many experiencing chronic symptoms, most days of the year. Beyond the physical toll, migraines exact a heavy emotional burden on sufferers, disrupting daily life, productivity, and overall well-being.

In recent years, hope emerged for many migraine sufferers with the introduction of new medications specifically designed to target the underlying mechanisms of migraine. Two such medications, Emgality and Ajovy, both belonging to the class of calcitonin gene-related peptide (CGRP) monoclonal antibodies, showed promising results in clinical trials. These medications were added to the Pharmaceutical Benefits Scheme (PBS), providing affordable access to thousands of Australian migraine sufferers. However, the current landscape is marred by a distressing reality: a nationwide shortage of these vital medications. This shortage stems from a supply issue, leaving many migraine sufferers without access to the relief they desperately need. Despite efforts to rectify the situation, a clear resolution remains elusive, leaving individuals reliant on these medications in a state of uncertainty and anxiety.

Amidst this challenging scenario, Dominic Forsythe, Principal Headache Clinician at the Gold Coast Headache & Migraine Clinic, recently shed light on the impact of this medication shortage in an interview with ABC radio. His insights underscored the urgent need for alternative approaches to migraine management. At the Gold Coast Headache & Migraine Clinic, Dominic and his team offer a beacon of hope for migraine sufferers grappling with the medication shortage.

The Gold Coast Headache & Migraine Clinic have developed a precise assessment technique focusing on the upper cervical spine. They identify potential triggers and sensitivities contributing to migraine episodes. Armed with this understanding, they tailor treatment plans to address the root causes of migraines, leading to significant reductions in symptom severity, frequency, and duration. A comprehensive treatment plan will include specific and targeted treatment to the cervical spine of affected migraineurs and headache sufferers. Alongside, their treatment plan addresses any contributing lifestyle or postural factors that may be impacting their condition even further.

Dominic’s expertise and dedication have transformed the lives of thousands of Gold Coast residents, not only by reducing their symptoms but also by enabling many to completely stop taking medication altogether. His holistic approach to migraine management has garnered praise from patients who have experienced lasting relief and regained control over their lives.

As the nationwide shortage of migraine medications persists, the need for proactive measures to manage migraines becomes increasingly critical. For Gold Coast residents enduring the debilitating effects of migraines, relief is within reach at the Gold Coast Headache & Migraine Clinic.

It’s time to act. If you or someone you know is struggling with migraines, don’t wait in despair. Call our clinic today at 1800 43 23 22 or book online at to embark on a journey towards lasting relief and reclaim control over your life.

Additionally, if you prefer, you can organise a free 10-minute phone call with Dominic Forsythe to discuss your condition further and explore how our clinic can assist you on your path to wellness.


Written By:

Dominic Forsythe

Principal Headache Clinician




1 Benhaddi H, McCabe S, Lau DT. 070 Burden of migraine in Australia: a systematic literature review. Journal of Neurology, Neurosurgery & Psychiatry 2019;90:A22.